146 related articles for article (PubMed ID: 33350587)
1. Non-proportional hazards in immuno-oncology: Is an old perspective needed?
Magirr D
Pharm Stat; 2021 May; 20(3):512-527. PubMed ID: 33350587
[TBL] [Abstract][Full Text] [Related]
2. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.
Mukhopadhyay P; Ye J; Anderson KM; Roychoudhury S; Rubin EH; Halabi S; Chappell RJ
JAMA Oncol; 2022 Sep; 8(9):1294-1300. PubMed ID: 35862037
[TBL] [Abstract][Full Text] [Related]
3. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
4. Sample size and power for the weighted log-rank test and Kaplan-Meier based tests with allowance for nonproportional hazards.
Yung G; Liu Y
Biometrics; 2020 Sep; 76(3):939-950. PubMed ID: 31797363
[TBL] [Abstract][Full Text] [Related]
5. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
6. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
7. Group sequential monitoring based on the maximum of weighted log-rank statistics with the Fleming-Harrington class of weights in oncology clinical trials.
Prior TJ
Stat Methods Med Res; 2020 Dec; 29(12):3525-3532. PubMed ID: 32522077
[TBL] [Abstract][Full Text] [Related]
8. A simulation-free group sequential design with max-combo tests in the presence of non-proportional hazards.
Wang L; Luo X; Zheng C
Pharm Stat; 2021 Jul; 20(4):879-897. PubMed ID: 33759337
[TBL] [Abstract][Full Text] [Related]
9. Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects.
Jiménez JL; Stalbovskaya V; Jones B
Pharm Stat; 2019 May; 18(3):287-303. PubMed ID: 30592138
[TBL] [Abstract][Full Text] [Related]
10. Introducing a new estimator and test for the weighted all-cause hazard ratio.
Ozga AK; Rauch G
BMC Med Res Methodol; 2019 Jun; 19(1):118. PubMed ID: 31185922
[TBL] [Abstract][Full Text] [Related]
11. The Inverse Log-Rank Test: A Versatile Procedure for Late Separating Survival Curves.
Efird JT
Int J Environ Res Public Health; 2023 Dec; 20(24):. PubMed ID: 38131716
[TBL] [Abstract][Full Text] [Related]
12. Comparison of survival distributions in clinical trials: A practical guidance.
Chen X; Wang X; Chen K; Zheng Y; Chappell RJ; Dey J
Clin Trials; 2020 Oct; 17(5):507-521. PubMed ID: 32594788
[TBL] [Abstract][Full Text] [Related]
13. A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects.
He P; Su Z
Contemp Clin Trials Commun; 2015 Oct; 1():28-31. PubMed ID: 29736436
[TBL] [Abstract][Full Text] [Related]
14. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
Jiménez JL
J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
[TBL] [Abstract][Full Text] [Related]
15. Sample size calculation for the combination test under nonproportional hazards.
Cheng H; He J
Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
[TBL] [Abstract][Full Text] [Related]
16. Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves.
Magirr D; Jiménez JL
Biom J; 2023 Apr; 65(4):e2200126. PubMed ID: 36732918
[TBL] [Abstract][Full Text] [Related]
17. Partitioned log-rank tests for the overall homogeneity of hazard rate functions.
Liu Y; Yin G
Lifetime Data Anal; 2017 Jul; 23(3):400-425. PubMed ID: 26995734
[TBL] [Abstract][Full Text] [Related]
18. Statistical and practical considerations in designing of immuno-oncology trials.
Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
[TBL] [Abstract][Full Text] [Related]
19. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
Wang Z; Zhang Q; Xue A; Whitmore J
Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
[TBL] [Abstract][Full Text] [Related]
20. A sample size formula for the supremum log-rank statistic.
Eng KH; Kosorok MR
Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
